P-glycoprotein transporters and the gastrointestinal tract: Evaluation of the potential in vivo relevance of in vitro data employing talinolol as model compound

International Journal of Clinical Pharmacology and Therapeutics

Volumn 36, Issue 1, 1998, Pages 16-24

  Spahn Langguth, H ^a   Baktir, G ^b   Radschuweit, A ^a   Okyar, A ^b   Terhaag, B ^c   Ader, P ^a   Hanafy, A ^a   Langguth, P ^d  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b ISTANBUL UNIVERSITY   (Turkey)

^c Arzneimittelwerk Dresden   (Germany)

^d ASTRAZENECA R AND D   (Sweden)

Author keywords

adrenoceptor antagonists; Bioavailability; Drug absorption; Intestinal secretion; P glycoprotein; Pharmacokinetics

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; GENE PRODUCT; GLYCOPROTEIN P; TALINOLOL; VERAPAMIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CELL STRAIN CACO 2; CONCENTRATION RESPONSE; CONFERENCE PAPER; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG PROTEIN BINDING; DRUG TRANSPORT; GASTROINTESTINAL TRACT; INTESTINE SECRETION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MONOLAYER CULTURE; MULTIDRUG RESISTANCE; NONHUMAN; ORAL DRUG ADMINISTRATION; PERMEABILITY; RAT;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; BIOLOGICAL AVAILABILITY; CACO-2 CELLS; CALCIUM CHANNEL BLOCKERS; DIGESTIVE SYSTEM; DRUG INTERACTIONS; HUMANS; INTESTINAL ABSORPTION; MALE; P-GLYCOPROTEIN; PROPANOLAMINES; RATS; RATS, WISTAR; VERAPAMIL;

EID: 0031962002     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (26)

1. Allen CN, Harpur ES, Gray TJH, Simmons NJ, Hirst BH 1990 Efflux of bis-carboxyethyl-carboxyfluorescein (BCECF) by a novel ATP-dependent transport mechanism in epithelial cells. Biochem Biophys Res Commun 172: 262-267
2. Anderle P, Niederer E, Spahn-Langguth H, Wunderli-Allenspach H, Merkle HP, Langguth P 1997 The influence of culturing conditions and drug exposure on P-glycoprotein expression in Caco-2 cells. Proc Intl Symp Control Rel Bioact Mater 24: 323-324
3. Aungst BJ, Saitoh H 1996 Intestinal absorption barriers and transport mechanisms, including secretory transport, for a cyclic peptide, fibrinogen antagonist. Pharm Res 13: 114-119
4. Döppenschmitt S, Spahn-Langguth H, Regardh C, Langguth P 1997 Radioligand binding assay employing P-glycoprotein-overexpressing intestinal cells: Testing drug affinities to the secretory intestinal multidrug transporter. Pharm Res to be submitted
5. Gramatte T, Oertel R, Terhaag B, Kirch W 1996 Direct demonstration of small intestinal secretion and site-dependent absorption of the β-blocker talinolol in humans. Clin Pharm Ther 59: 541-549
6. Hanafy A, Hilgendorf C, Ader P, Langguth P, Spahn-Langguth H 1997 The distomer may increase the bioavailability of the eutomer: Alteration of in-situ and in-vitro permeabilities of S- and R-talinolol by P-glycoprotein modulators. Pharm Res to be submitted
7. Hilgendorf C, Spahn-Langguth H, Lipka E, Croyle M, Amidon GL, Langguth P 1997a Comparative characterization of Caco-2/HT29-MTX co-cultured cell lines: Permeabilities via diffusion and inside- and outside-directed carrier-mediated transport. Pharm Res to be submitted
8. Hilgendorf C, Langguth P, Lipka E, Amidon GL, Spahn-Langguth H 1997b Stereoselectivity of intestinal secretion processes: Studies with the β-adrenoceptor antagonist talinolol and related compounds in cell-culture based absorption models. Chirality to be submitted
9. Hunter J, Hirst BH 1997 Intestinal secretion of drugs: The role of P-glycoprotein and related efflux systems in limiting drug absorption. Adv Drug Deliv Rev 25: 129-157
10. Karlsson J, Kuo SM, Ziemniak J, Artursson P 1993 Transport of celiprolol across human intestinal epithelial (Caco-2) cells: Mediation of secretion by multiple transporters including P-glycoprotein. Br J Pharmacol 110: 1109-1013
11. Langguth P, Amidon GL, Lipka E, Spahn-Langguth H 1997 Gastrointestinal transport processes: Potentials for stereoselectivities at substrate-specific and nonspecific epithelial transport systems, chapter 22. In: Aboul-Eneim HY, Wainer IW (eds) The Impact of Stereochemistry on Drug Development and Use. Chemical Analysis Series. John Wiley and Sons, New York, pp 611-632
12. 4 and structurally related conjugates. J Biol Chem 265: 27807-27810
13. Lennernäs H, Regardh CG 1993 Dose-dependent intestinal absorption and significant intestinal secretion (exsorption) of the beta-blocker pafenolol in the rat. Pharm Res 10: 879-883
14. Lesuffleur T, Barbat A, Dussaulx, Zweibaum A 1990 Growth adaptation to methotrexate of HT-29 human colon carcinoma cells is associated with their ability to differentiate into columnar absorptive and mucus-secreting cells. Cancer Res 50: 6334-6343
15. Lipka E, Spahn-Langguth H, Mutschler E, Amidon GL 1997 In vivo nonlinear intestinal permeability of celiprolol and propranolol in conscious dogs: Evidence for intestinal secretion. Eur J Pharm Sci in press
16. Lucas ML, Blair JA 1978 The magnitude and distribution of the acidic microclimate in the proximal jejunum and its relation to luminal acidification. Proc Royal Soc Lond 200: 27-41
17. Pritchard JB, Miller DS 1997 Renal secretion of organic cations: A multistep process. Adv Drug Deliv Rev 25: 231-242
18. Prueksaritanont T, Gorham LM, Hochman JH, Lekhanh OT, Kamlesh PV 1996 Comparative studies of drug-metabolizing enzymes in dog, monkey, and human small intestine, and in Caco-2 cells. Drug Metab Dispos 24: 634-642
19. Raeissi SD, Guo Z, Dobson GL, Artursson P, Hidalgo IJ 1997 Comparison of CYP3A activities in a subclone of Caco-2 cells (TC7) and human intestine. Pharm Res 14: 1019-1025
20. Schinkel AH, Smit JJM, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CAAM, van der Valk MA, Robanus-Maandag EC, te Riele HPJ, Berns AJM, Borst P 1994 Disruption of the mouse MDR1a P-glycoprotein gene leads to deficiency of the blood-brain barrier and to increased sensitivity to drugs. Cell 77: 491-502
21. Spahn H, Wellstein A, Pflugmann G, Mutschler E, Palm D 1989 Radioreceptor assay of metoprolol in human plasma: Comparison with an enantiospecific high-performance liquid chromatographic (HPLC) procedure. Pharm Res 5: 107-112
22. Spahn-Langguth H, Benet LZ, Möhrke W, Langguth P 1997 First-pass phenomena: Sources of stereoselectivities and variabilities of concentration-time profiles after oral dosage, chapter 21. In: Aboul-Enein HY, Wainer IW (eds) The Impact of Stereochemistry on Drug Development and Use. Chemical Analysis Series. John Wiley and Sons, New York, pp 573-610
23. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I 1987 Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 84: 7735-7738
24. Trezise AE, Romano PR, Gill DR, Hyde SC, Sepulveda FV, Buchwald M, Higgins CF 1992 The multidrug resistance and cystic fibrosis genes have complementary pattern of epithelial expression. EMBO J 11: 4291-4303
25. Wetterich U, Spahn-Langguth H, Mutschler E, Terhaag B, Rösch W, Langguth P 1996 Evidence for intestinal secretion as additional clearance pathway of talinolol enantiomers: Concentration- and dose-dependence absorption in vitro and in vivo. Pharm Res 13: 514-522
26. Zevin S, Illsley NP, Schaner ME, Giacomini KM 1997 Guanidine transport in a human choriocarcinoma cell line. Pharm Res 14: 401-405